GILD Gilead Sciences

XNGS Up Alert

Health Care

· How we analyze

About the company

Gilead Sciences is a US biotechnology company. Its focus is drugs for HIV, hepatitis B and C and cancer therapies, including cell therapies. Well-known products include the HIV drug Biktarvy and the Covid drug Veklury. As of Oct 11, 2026

Fact sheet (from the annual report) Biotechnology and vaccines · Foster City, USA

The biopharmaceutical company, based in Foster City, offers medicines for HIV, viral hepatitis, COVID and cancer. For HIV it markets Biktarvy and Descovy, among others. In liver disease it markets Epclusa for chronic hepatitis C, also as an authorized generic through a subsidiary. In oncology it offers a cell therapy for certain forms of lymphoma and leukemia and an antibody-drug conjugate for certain forms of breast cancer. In the US market, sales and distribution of most products run exclusively through wholesalers, mainly Cardinal Health, Cencora and McKesson. Outside the US market it sells through its own teams, external distributors or partners, and manufacturing is in part done by contract manufacturers.

Automatically summarized from SEC annual report (10-K, filed Feb 24, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 14, 2026

Price performance at a glance

Last 30 trading days
  • Today +0.3%
  • 7 days +1.6%
  • 30 days +5.4%
  • 1 year +32.1%
Day range (last trading day)
−2.1%Price at 94% of the range+0.1%
52-week range
−28.3%Price at 97% of the range+0.9%
Distance from the all-time high
−0.9%

Our own calculation from the exchange’s daily candles, as of Oct 27, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.

Gap with volume · Analysis method

The price of GILD is currently in no zone of this method. The check runs daily after the market close.

Whether a price will soon reach a zone, you see from Watcher. Plans and pricing

How the zone is formed

What is this? After strong news, usually earnings, the price opened above the previous day’s high and closed much higher on heavy volume. Such moves often continue for a few more days.

Buy zone: from the start of the gap to the close of the gap day. Stop: just below the low of the gap day. Targets: 3 and 5 ATR (normal daily ranges) above the close of the gap day.

The pattern is valid for at most 15 trading days and expires if the price falls below the stop. This is a calculated analysis, not a forecast and not a call to buy. Risk notice and investment advice

Load chart from TradingView

This transfers data (including your IP address) to TradingView, also to the USA. More in the Privacy policy.

Symbol on TradingView: NASDAQ:GILD

Save zone

With a free account: save the buy zone shown for yourself (stop and targets from Watcher). It stays visible even if the zone changes later. Log in · Sign up

Fundamental analysis

Gilead Sciences · Sector Health Care · amounts in USD

Information only – does not affect our buy zones, not investment advice. Source: SEC filings, As of Feb 24, 2026.

In short

  • Light yellow: Revenue grew over 5 years (+3.6% per year), more slowly than the sector median.
  • Light green: Net income (total) grew over 5 years (+133.3% per year), at least as fast as the sector median; per share +132.4% per year.
  • Light green: Net margin 28.9%, above the sector median (12.9%).
  • Light red: Debt much higher than usual in the sector.
  • Light green: Profit in each of the last 10 fiscal years.

Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.

RevenueNet income Net margin (below) in USD
  1. Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Revenue 30.4B USD · Net income 13.5B USD · Net margin 44.4%
  2. Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Revenue 26.1B USD · Net income 4.6B USD · Net margin 17.7%
  3. Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Revenue 22.1B USD · Net income 5.5B USD · Net margin 24.7%
  4. Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Revenue 22.4B USD · Net income 5.4B USD · Net margin 24.0%
  5. Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Revenue 24.7B USD · Net income 123.0M USD · Net margin 0.5%
  6. Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Revenue 27.3B USD · Net income 6.2B USD · Net margin 22.8%
  7. Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Revenue 27.3B USD · Net income 4.6B USD · Net margin 16.8%
  8. Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Revenue 27.1B USD · Net income 5.7B USD · Net margin 20.9%
  9. Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Revenue 28.8B USD · Net income 480.0M USD · Net margin 1.7%
  10. Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 29.4B USD · Net income 8.5B USD · Net margin 28.9%

Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 29.4B USD · Net income 8.5B USD · Net margin 28.9%

Key figures with traffic lights

Each light follows a simple, disclosed rule. The comparison is with the sector median of all 63 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).

Revenue growth

Light yellow: below sector

+3.6% per year, last 5 years

Sector Health Care: median +7.8% (60 symbols)

What does this mean? Revenue: over 5 years it grew by 3.6% per year on average, but more slowly than the median company in the sector (+7.8%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net income (total)

Light green: above sector

+133.3% per year, last 5 years

Sector Health Care: median +7.5% (46 symbols)

per share: +132.4% per year (5 years, split-adjusted)

What does this mean? Total net income: over 5 years it grew by 133.3% per year on average – at least as fast as the median company in the sector (+7.5%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net margin

Light green: above sector

28.9% last fiscal year

Sector Health Care: median 12.9% (63 symbols)

What does this mean? Of every 100 USD in revenue, 28.90 USD remained as profit – at least as much as the median company in the sector (12.9%). Five years ago the margin was 0.5%.

Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.

Debt / equity

Light red: much higher

2.22 latest balance sheet

Sector Health Care: median 0.66 (40 symbols)

What does this mean? For every 1 USD of equity there is 2.22 USD of financial debt – more than twice as much as the median company in the sector (0.66). More debt amplifies good and bad years alike.

Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.

Payout ratio

Light green: covered

47% Dividend / earnings per share

Sector Health Care: median 28% (31 symbols)

What does this mean? Of every 1 USD of earnings per share, 0.47 USD went to shareholders as a dividend. The rest stays in the company. Median company in the sector: 28%.

Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.

Profitable years

Light green: profit every year

10 of 10 fiscal years with a profit

What does this mean? In 10 of the last 10 fiscal years the bottom line showed a profit. There were no losses in this period.

Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).

Last fiscal year and 13F

Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
29.4B USD
Revenue vs. prior year
+2.4%
Net income (FY)
8.5B USD
Net income vs. prior year
+1,672.9%
EPS (FY)
6.78 USD
13F funds with a position
2 of 9
Funds vs. prior quarter
±0
Shares held vs. prior quarter
+2,151.6%
Fiscal year to Dec 31, 2025 · 10-K filed Feb 24, 2026 · Balance sheet Jun 30, 2026 (filed Aug 6, 2026) · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term). 13F: reporting date Jun 30, 2026, 9 tracked funds have filed (latest Aug 14, 2026), filed with up to 45 days of delay. Stock positions only; comparison with Mar 31, 2026 only across funds that filed for both quarters.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
YearEndRevenueNet income MarginEarnings per shareDividend per sharePayout
2025Dec 31, 2025 29.4B8.5B 28.9% 6.78 3.16 47%
2024Dec 31, 2024 28.8B480.0M 1.7% 0.38 3.08 811%
2023Dec 31, 2023 27.1B5.7B 20.9% 4.50 3.00 67%
2022Dec 31, 2022 27.3B4.6B 16.8% 3.64 2.92 80%
2021Dec 31, 2021 27.3B6.2B 22.8% 4.93 2.84 58%
2020Dec 31, 2020 24.7B123.0M 0.5% 0.10 2.72 2,720%
2019Dec 31, 2019 22.4B5.4B 24.0% 4.22 2.52 60%
2018Dec 31, 2018 22.1B5.5B 24.7% 4.17 2.28 55%
2017Dec 31, 2017 26.1B4.6B 17.7% 3.51 2.08 59%
2016Dec 31, 2016 30.4B13.5B 44.4% 9.94 1.84 19%
Quarters (amounts in USD, per share in USD)
QuarterEndRevenueNet income MarginEarnings per shareDividend per sharePayout
Q2/26Jun 30, 2026 7.8B−10.5B −134.5% −8.45 0.82 –
Q1/26Mar 31, 2026 7.0B2.0B 29.0% 1.61 0.82 51%
Q4/25*Dec 31, 2025 7.9B2.2B 27.5% – 0.79 –
Q3/25Sep 30, 2025 7.8B3.1B 39.3% 2.43 0.79 33%
Q2/25Jun 30, 2025 7.1B2.0B 27.7% 1.56 0.79 51%
Q1/25Mar 31, 2025 6.7B1.3B 19.7% 1.04 0.79 76%
Q4/24*Dec 31, 2024 7.6B1.8B 23.6% – 0.77 –
Q3/24Sep 30, 2024 7.5B1.3B 16.6% 1.00 0.77 77%
Q2/24Jun 30, 2024 7.0B1.6B 23.2% 1.29 0.77 60%
Q1/24Mar 31, 2024 6.7B−4.2B −62.4% −3.34 0.77 –
Q4/23*Dec 31, 2023 7.1B1.4B 20.1% – 0.75 –
Q3/23Sep 30, 2023 7.1B2.2B 30.9% 1.73 0.75 43%

* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.

How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.

Insiders

All insider transactions
Insider purchases and sales on the market over 3, 6 and 12 months
PeriodPurchasesSalesNet
3 months $00 people $15.9M5 people −$15.9M
6 months $00 people $26.6M5 people −$26.6M
12 months $00 people $87.9M7 people −$87.9M

Latest transactions

  • Oct 15, 2026 Mercier Johanna Officer Open-market sale · 10b5-1 plan 3,000 shares · $468.7K · SEC
  • Oct 15, 2026 Dickinson Andrew D Chief financial officer (CFO) Open-market sale · 10b5-1 plan 3,000 shares · $468.7K · SEC
  • Oct 1, 2026 O'Day Daniel Patrick Chief executive (CEO), Director Open-market sale · 10b5-1 plan 3,000 shares · $445.9K · SEC
  • Oct 1, 2026 O'Day Daniel Patrick Chief executive (CEO), Director Open-market sale · 10b5-1 plan 12,000 shares · $1.8M · SEC
  • Sep 15, 2026 Mercier Johanna Officer Open-market sale · 10b5-1 plan 600 shares · $87.2K · SEC
  • Sep 15, 2026 Mercier Johanna Officer Open-market sale · 10b5-1 plan 800 shares · $115.6K · SEC

Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.

Trend score +75

Price vs. EMA 50+15
Price vs. EMA 200+15
EMA 50 vs. EMA 200+20
ADX (trend strength)+0
Highs and lows+10
Relative strength+15

Volatility and trend strength

ADX 14 (trend strength)22.6
Rel. strength 60 d+20.1%

ATR and moving averages as price values only when logged in.

More stocks from Health Care

All symbols in this sector

News

Latest news

Posts

No posts on GILD yet – log in to join the discussion.

Posts are opinions of users and only visible after logging in. Community rules

Set alert: GILD

Alerts with a free account: we send you an email as soon as the price moves above or below your level, reaches the buy zone or the buy zone becomes invalid.

Checked after every data update: crypto hourly (buy zones every 4 hours), stocks twice a day, precious metals every 4 hours on trading days, extended universe weekly – not in real time.

Log in Sign up free

↑ ↓ select · Enter open · Esc close